加载中...

MedXY AI/MedXY News/Tag: cardiovascular risk

MedXY News

EnglishTag

cardiovascular risk

75 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control ( **Confirming JSON Structure** I’m now fully focused on creating the JSON object. I’ve re-reviewed both schemas, and am following the most up-to-date

Section: CardiologyFeb 24, 2026

Beyond Stenosis: Why Quantitative Plaque Volume Is the New Frontier in Cardiovascular Risk Assessment

Beyond Stenosis: Why Quantitative Plaque Volume Is the New Frontier in Cardiovascular Risk Assessment

A substudy of the PROMISE trial demonstrates that quantitative plaque measures on CCTA—specifically total and noncalcified plaque burden—independently predict major adverse cardiovascular events in symptomatic outpatients, offering a precis

Section: CardiologyFeb 22, 2026

RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk

RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk

A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the c

Section: CardiologyFeb 6, 2026

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate

Section: CardiologyFeb 4, 2026

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv

Section: CardiologyJan 17, 2026

Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes

Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes

A post-hoc analysis of the ACCORD trial reveals that intensive blood pressure control significantly reduces cardiovascular and stroke risk in haptoglobin 1 allele carriers, but not in those with the Hp2-2 phenotype, suggesting a genotype-dr

Section: CardiologyJan 7, 2026

Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years

Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years

A landmark Swedish cohort study demonstrates that diabetes subgroups, particularly those characterized by insulin resistance and deficiency, carry significantly higher risks for end-organ damage and cardiovascular mortality than previously

Section: CardiologyJan 7, 2026

Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels

Lowering Blood Pressure in Isolated Diastolic Hypertension: Evidence Supports Risk Reduction Across All Diastolic Levels

A large-scale meta-analysis reveals that lowering blood pressure in patients with isolated diastolic hypertension (IDH) provides cardiovascular protection comparable to those with systolic elevations, suggesting that diastolic thresholds al

Section: CardiologyJan 6, 2026

Synergistic Integration of Metabolomics and Polygenic Scores Doubles the Impact of Cardiovascular Risk Prediction Models

Synergistic Integration of Metabolomics and Polygenic Scores Doubles the Impact of Cardiovascular Risk Prediction Models

A large-scale UK Biobank study demonstrates that combining NMR metabolomics and polygenic risk scores with the SCORE2 framework significantly improves cardiovascular risk discrimination, potentially doubling the number of preventable events

Section: CardiologyJan 6, 2026

Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction

Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction

Recent large-scale studies demonstrate that high-sensitivity C-reactive protein (hsCRP) is a potent, stable predictor of cardiovascular events, even in individuals without traditional risk factors. Despite its clinical utility in improving

Section: CardiologyJan 5, 2026

Elevated LDL-C Increases Cardiovascular Risk in Symptomatic Patients Despite a Coronary Calcium Score of Zero

Elevated LDL-C Increases Cardiovascular Risk in Symptomatic Patients Despite a Coronary Calcium Score of Zero

A large-scale cohort study from the Western Denmark Heart Registry demonstrates that high LDL-C remains a significant predictor of non-calcified plaque and coronary heart disease events in patients with a CAC score of zero, particularly amo

Section: CardiologyJan 4, 2026

Timing Matters: Delayed Statin Initiation After Incidental High LDL-C Detection Significantly Increases Myocardial Infarction Risk

Timing Matters: Delayed Statin Initiation After Incidental High LDL-C Detection Significantly Increases Myocardial Infarction Risk

A large-scale cohort study demonstrates that delaying statin therapy following the incidental discovery of high LDL-C during routine health screenings leads to a progressively higher risk of myocardial infarction, emphasizing the critical i

Section: CardiologyJan 4, 2026

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk

Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk

Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p

Section: Internal MedicineJan 1, 2026

AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases

AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases

AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.

Section: AIDec 25, 2025

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped associati

Section: CardiologyDec 25, 2025

Preoperative Cardiovascular Risk Does Not Dictate RAS Inhibitor Management: Insights from the STOP-or-NOT Trial

Preoperative Cardiovascular Risk Does Not Dictate RAS Inhibitor Management: Insights from the STOP-or-NOT Trial

A post hoc analysis of the STOP-or-NOT trial demonstrates that preoperative cardiovascular risk stratification does not influence the outcomes of continuing versus discontinuing renin-angiotensin system inhibitors before major noncardiac su

Section: AnesthesiologyDec 23, 2025

Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks

Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks

Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.

Section: CardiologyDec 16, 2025

Beyond the Lesion: Long-Term Cardiovascular, Neurologic, Psychiatric, and Endocrine Risks After Traumatic Spinal Cord Injury

Beyond the Lesion: Long-Term Cardiovascular, Neurologic, Psychiatric, and Endocrine Risks After Traumatic Spinal Cord Injury

A large retrospective cohort study shows traumatic spinal cord injury (TSCI) is associated with increased long-term cardiovascular, neurologic, psychiatric, and endocrine morbidity and higher mortality, even in previously healthy adults.

Section: CardiologyDec 15, 2025

Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts

Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts

This review synthesizes evidence on the performance of AHA PREVENT equations in individuals with elevated lipoprotein(a), emphasizing its independent risk association and potential to enhance personalized ASCVD risk prediction.

Section: CardiologyDec 3, 2025

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among thos

Section: CardiologyNov 30, 2025

Prev 1 2 3 4 Next